中文
English
한국어
日本語
Español
Français
Русский
| 카탈로그 번호 | HB103036 |
|---|---|
| 종 반응성 | Human |
| 응용 분야 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 숙주 종 | Human |
| 클론성 | Monoclonal |
| 이소타입 | IgG |
| 클론 ID | BI-1206 |
| 생물학적 활성 | BI-1206 (5 ug/mL, 0-5 h) blocks Rituximab (5 ug/mL)-induced and Rituximab-based combination with Ibrutinib or Venetoclax or CHOP-induced CD20 internalization effectively in JeKo-1 cells [1]. BI-1206 (10 mg/kg, i.v., twice a week) is highly potent in blocking tumor growth in Ibrutinib-Venetoclax dual resistant MCL PDX (PDX-A) NSG mice model [1]. BI-1206 (10 mg/kg, i.v., twice a week) inhibits tumor growth when combined with Rituximab in Rituximab-Ibrutinib-CAR T-triple resistant MCL PDX (PDX-B) NSG mice model [1]. BI-1206 (10 mg/kg, i.v., twice a week for 14 d) has better efficacy and prolonged survival in the triple combination group with Ibrutinib or Venetoclax compared to dual combinations without BI-1206 in JeKo-1 CDX mice model [1]. BI-1206 (10 mg/kg, i.v., twice a week) shows superior anti-tumor activity and prolonged survival when combined with Venetoclax compared to any single or dual combination in Ibrutinib-Rituximab-Venetoclax triple-resistant MCL PDX (PDX-C) model [1]. |
| 발현 시스템 | Mammalian cells |
| 타겟 | IGFR2, FCG2, Fc-gamma RII-b, CDw32, FcRII-b, IgG Fc receptor II-b, CD32, Fc-gamma-RIIb, Low affinity immunoglobulin gamma Fc region receptor II-b, FCGR2B |
| 내독소 수준 | < 10 EU/mg |
| 순도 | >95% purity as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | P31994 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 대체 이름 | BI-1206, BI1206, BI1206 |
| 배경 | Low affinity immunoglobulin gamma Fc region receptor II-b (CD32b/FCGR2B) is a ~34 kDa protein. Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. |
| 참고 문헌 | 1. Jiang VC, et al., Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma. J Hematol Oncol. 2022 Apr 11;15(1):42. [HB103036] 2. Changying Jiang, et al., BI-1206, a Monoclonal Antibody Against Fcγriib, Showed Superior Anti-Tumor Activity in an Ibrutinib-Venetoclax Dual Resistant PDX Model in Mantle Cell Lymphoma, Blood, Volume 134, Supplement 1, 2019, Page 2863, ISSN 0006-4971. [HB103036] 3. Mårtensson, L.et al., A novel FcγRIIB-blocking antibody to enhance FcγR-dependent antitumor immunity with anti-HER2 therapy[J]. Cancer Research, 2022, 82(12_Supplement): 3423-3423. [HB103036] |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1, lambda Isotype Control antibody (HyHEL-10) (HP248107) |
SDS-PAGE for Research Grade Anti-Human CD32b/FCGR2B (BI-1206)
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206
